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Objective 
To describe the use of Lactobacillus by hospitalized patients and to examine its 
relationship with various Clostridium difficile infection (CDI) related outcomes. 
Methods 
The characteristics of Lactobacillus users and non-users and the initiation of 
Lactobacillus with respect to initiation of antibiotic therapy and CDI treatment were 
described using national hospital discharge database. The relationships between 
xi 
 
Lactobacillus use and post-CDI length of stay, mortality, switch of CDI therapy, and 
readmission were analyzed. 
Results 
Lactobacillus users and non-users were different in most characteristics. 
Metronidazole and fluoroquinolones were the most frequently used antibiotics by 
Lactobacillus users. They were mainly CDI cases, used multiple antibiotics, extremely ill, 
and started Lactobacillus five or more days after initiation of antibiotics or CDI treatment. 
Lactobacillus use was associated with increased length of stay and switching of CDI 
therapy. 
Conclusions 
The true association between Lactobacillus use and CDI remains unclear. This 
study provides foundation for future research. 
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CHAPTER 1 INTRODUCTION 
 
Background 
Clostridium difficile is a gram-positive anaerobic spore-forming rod-shaped 
bacteria (bacillus). C. difficile produces two potent toxins: toxin A which is an enterotoxin, 
and toxin B which is a cytotoxin. Both are implicated in the pathogenesis of C. difficile 
infection (CDI). They act synergistically and are capable of damaging the human colonic 
epithelium.1, 2 
The severity of CDI ranges from mild diarrhea to life-threatening conditions, such 
as pseudomembranous colitis and toxic megacolon.3, 4 CDI is the leading identified type of 
nosocomial diarrhea.5 In addition, it is implicated in 20% to 30% of patients with 
antibiotic-associated diarrhea (AAD) and in more than 90% of those with antibiotic-
associated pseudomembranous colitis.1, 2 CDI may result in an increased length of stay by 
three to seven days, as well as a 20% to 65% increase in the rate of subsequent infections. 
There may also be a two- to three-fold increase in mortality as a result of CDI.6-8 In 
addition to these clinical consequences, the long-term costs attributed to CDI in the United 
States in 2003 were estimated to be between $897 million and $1.3 billion.1, 2, 10, 11 
Current treatment strategies of CDI consist of discontinuing the offending 
antibiotic, if possible, and initiating antibacterial treatment, which could be either oral 
metronidazole or oral vancomycin. Unfortunately, these treatment strategies are associated 
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with a high recurrence rate of up to 28 %.6, 12 Some evidence shows that oral teicoplanin 
may be a better choice than vancomycin in some cases, but this agent is not available in the 
United States.13 
Probiotics, defined as live microbial dietary supplements that beneficially affect the 
host by improving intestinal microbial balance,15 have been used as a way of restoring 
intestinal microflora. This acts as a protective barrier that resists the colonization of 
intestinal pathogens and consequently decreases the incidence and duration of antibiotic-
associated diarrhea in general. Probiotics may also prevent CDI. They are relatively 
inexpensive, generally safe and well tolerated.16 
There have been several studies reported in the last three decades looking at the 
effect of probiotics on the treatment of CDI.7, 8, 18-26 These studies yielded contradictory 
results because of differences in study design, type and duration of probiotics therapy, 
differing doses and durations of antibiotic treatment. There are different types of probiotics 
that have variable efficacy in the prevention and treatment of CDI. Lactobacillus 
rhamnosus GG (LGG) and Saccharomyces boulardii were shown to be more effective than 
other probiotics. In addition, they have many other potential positive health effects.24, 27, 28 
McFarland et al. studied the effect of adding S. boulardii to the regular treatment of 
CDI. Compared to the control group, they found that the S. boulardii group was 
significantly more likely to respond to antibiotic therapy and less likely to experience 
recurrence of diarrhea.24 Surawicz et al. in similar study found that the high dose 
vancomycin group with S. boulardii demonstrated decreased frequency of CDI 
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recurrence.22 Wullt et al. found no significant differences between the two groups in the 
cure rate of initial CDI or the recurrence of CDI.20 
 
Objectives and Specific Aims 
The main objective of this study is to describe the use of a blend of Lactobacillus 
acidophilus and Lactobacillus helveticus (Lactinex®, Becton-Dickson, Co.) by CDI 
patients.29 The secondary objective is to examine the relationship between the use of 
Lactobacillus and various CDI related clinical outcomes. 
The project has the following specific aims: 
Specific Aim 1: Describe the demographic and clinical characteristics (age, gender, 
and race, CDI status, number of antibiotics received, transfer status, severity of 
illness, mortality, readmission, and overall length of stay) of patients who did and did 
not receive Lactobacillus.  
Specific Aim 2: Describe the initiation of Lactobacillus with respect to initiation of 
initial antibiotic therapy among patients who were on Lactobacillus. 
Specific Aim 3: Describe the initiation of Lactobacillus with respect to the initiation 
of CDI treatment among patients who were on Lactobacillus and had CDI. 
Specific Aim 4: Among patients who had nosocomial CDI, examine the relationship 
between Lactobacillus use and: 
a. Length of stay 
b. Switch rate of CDI treatment (i.e., metronidazole to vancomycin or vice versa)   
c. Readmission with CDI 
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d. Mortality 
 
Significance 
Based on review of published research, this study is the first descriptive study of 
the use of probiotics in CDI patients using a relatively large sample size.  A meta-analysis 
by McFarland compared the efficacy of probiotics for the treatment of CDI based on the 
published randomized clinical trials (RCTs) in adult hospitalized patients. This meta-
analysis concluded that probiotic therapy is effective in the treatment for CDI. The pooled 
relative risk from the six RCTs included was 0.59 (0.41, 0.85) for CDI in probiotics users. 
The heterogeneity of the included studies was not significant; however, the relatively small 
number of trials included could be a limiting factor in this meta-analysis.18 
Several methodological issues have plagued prior research on the use of probiotics 
in CDI patients including small sample sizes, inappropriate or inadequate control groups, 
and lack of control for co-morbidities and other confounders.18, 20, 22, 24, 25, 30, 31 
Additionally, these studies have shown contradictory results of the effect of Lactobacillus 
on the treatment of CDI primarily because of insufficient power to detect significant 
differences due to differences in the study population, type and dose of probiotics given, or 
the duration of treatment.18, 19 
This study seeks to describe the demographic and clinical characteristics of 
Lactobacillus users and non-users utilizing information from the Clinical Resource 
Manager (CRM) administrative database from the University HealthSystem Consortium 
(UHC) [Specific Aims 1-3]. This database has a large number of hospitalized patients from 
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participating teaching hospitals around the nation. Additionally, this study examines the 
relationship between the use of Lactobacillus by CDI patients and various related health 
outcomes [Specific Aim 4]. The findings of this study could be used to generate 
hypotheses for future studies. 
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CHAPTER 2 LITERATURE REVIEW 
 
 
Antibiotic-Associated Diarrhea 
Antibiotic-associated diarrhea (AAD) is defined as otherwise unexplained diarrhea 
that occurs in association with the administration of antibiotics.32 Clindamycin, 
cephalosporins, broad-spectrum penicillins, and fluoroquinolones are more likely to cause 
the problem than other antibiotics, even though all antibiotics are implicated.53 The rates of 
diarrhea associated with parenterally administered antibiotics, especially those with 
enterohepatic circulation, are similar to rates associated with orally administered agents.33 
The incidence of AAD in hospitalized adult patients could be (13–29%), or even up to 
60% during hospital outbreaks, but is rare in an out-patient and ambulatory setting 
(<0.1%).34, 35 The primary cause of AAD is the disruption of intestinal normal flora by 
antibiotics, which may lead to overgrowth of pathogens and colonization of the intestine. 
The most commonly diagnosed and potentially severe form of AAD is caused by C. 
difficile. This pathogen is implicated in 20% to 30% of patients with AAD, in 50% to 70% 
of those with antibiotic-associated colitis, and in nearly all cases of antibiotic-associated 
pseudomembranous colitis.2,36 Besides C. difficile infection, other factors involved in AAD 
include overgrowth of other pathogens, impaired fecal fermentation, and changes in dietary 
fiber intake.37, 38 
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Pathogenesis of AAD 
Figure 2.1 below shows the pathogenesis of AAD. The primary cause of AAD is 
the disruption of intestinal normal flora which acts as a protective barrier that resists the 
colonization of pathogens in the intestine.36 
 
 
  
Figure 2.1. Pathogenesis of antibiotic associated diarrhea (Adapted from Ref. 36) 
8 
 
In addition, the disruption of intestinal normal flora diminishes its function of 
digestion of non-absorbable carbohydrates, normally metabolized by colonic bacteria as an 
energy source. The production of lactic acid and short-chain fatty acids by the anaerobic 
flora is decreased, which increases the osmotic pressure in the colon. That reduces 
absorption of water and electrolytes in the colon and results in osmotic diarrhea.39 
Other factors potentially implicated in the pathogenesis of AAD are related to some 
antibiotic, such as penicillins, allergic and toxic effects on intestinal mucosa and to some 
antibiotic, such as macrolides, pharmacologic effects on intestinal motility. C. difficile is 
another important etiology of AAD.28 
 
Clostridium Difficile Infection 
Clostridium difficile infection (CDI) is most commonly associated with the 
exposure to antibiotics, especially cephalosporins, broad spectrum penicillins, 
clindamycin, and fluoroquinolones.53 A small but increasing percentage of cases may also 
experience megacolon, perforation, colectomy, or death. Patients with CDI may have an 
increase in the length of stay by 8 to 36 days, a 20% to 65% increase in the rate of 
subsequent infections, as well as a two- to three-fold increase in mortality.6-8, 42 In addition, 
CDI incurs substantially greater costs. 1, 2, 10, 11 
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Epidemiology of CDI 
C. difficile is the most common identified cause of nosocomial diarrhea. In a recent 
study, C. difficile was determined to be the causative agent of diarrhea in 19 out of 44 
(43%) patients with nosocomial diarrhea.40, 41 This pathogen is implicated in about 10% of 
cases of nosocomial diarrhea, 20% to 30% of patients with AAD, in 50% to 70% of those 
with antibiotic-associated colitis, and in nearly all cases of antibiotic-associated 
pseudomembranous colitis.1, 2, 36 In 1995, Barbut et al. found that the prevalence of CDI in 
patients who were suspected of having nosocomial diarrhea was 35 out of 344 (10.2%).42 
In a similar retrospective study by Rohner et al. in 1998, the prevalence rate was 248 out of 
2,531 (9.8%).43 The clinical presentations of CDI include lower abdominal discomfort, 
diarrhea, colitis, and in severe cases can result in pseudomembranous colitis, toxic 
megacolon, or death.44 About 3.2% of patients with CDI have complications requiring 
colectomy, while in 1%-2% of patients it results in death.45, 46 However, this figures 
dramatically increases in severe cases. In 2001, Barbut found that among patients requiring 
a colectomy for toxic megacolon or perforation, the mortality rate was 35%-50%.42  
In hospitals and long-term facilities, CDI is more common, with estimates of 25-60 
cases per 100,000 occupied bed-days, compared to 7.7 cases per 100,000 person-years in 
the community.47 A surveillance study in 2009 found similar results in Canadian hospitals 
with an overall incidence rate of nosocomial CDI for hospitalized adult patients of 4.6 
cases per 1,000 patient admissions or 65 per 100,000 patient-days.5 Among hospitalized 
children, a study by Kim et al. in the United Sates found that the annual incidence of CDI 
was 6.5 cases per 10,000 patient-days and 4.0 cases per 1,000 admissions.48 
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During the current decade, there has been a dramatic increase in the incidence and 
severity of CDI in healthcare settings. Based on the International Classification of 
Diseases, 9th Revision, Clinical Modification (ICD-9-CM) code for CDI (008.45), to 
measure CDI prevalence, McDonald et al. found that the proportion of hospital discharges 
with CDI code increased from 0.37% in 2000 to 0.51% in 2003 for an estimated 178,000 
CDI cases in patients discharged from short stay hospitals in 2003.49 These clinically 
relevant changes are temporally associated with the emergence of a hypervirulent strain of 
C. difficile that has now become widely disseminated.50 
 
CDI Impact on the Healthcare System 
A recent study by Marya et al. found that there was a 23% annual increase in CDI 
hospitalizations in the 6-year period from 2000 through 2005. Also, the absolute number of 
CDI hospitalizations more than doubled in almost all age groups as shown in Table 2.1 or 
Figure 2.2.51 
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Table 2.1 – Absolute numbers of adult hospitalizations with Clostridium difficile, by 
age group, United States, 2000–2005 
 
Hospitalizations 2000 2001 2002 2003 2004 2005 
18–44 y  14,738 15,001 18,747 19,393 22,168 25,662 
45–64 y  28,280 29,527 39,421 43,290 50,898 61,757 
65–84 y  69,018 74,010 98,148 105,404 122,875 147,675 
>85 y  22,325 25,194 31,899 35,363 43,341 56,209 
All adult  134,361 143,732 188,215 203,450 239,282 291,303 
(Source: Ref. 51) 
 
 
 
 
Figure 2.2 – Changes in the age-specific Clostridium difficile–associated disease 
incidence rate per 10,000 population in the United States, 2000–2005. (Source: 
Ref. 51)  
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The length of hospital stay for patients with CDI was found to increase by 8 days 
among adult inpatients and 36 days in geriatric patients.42 McFarland et al. found that costs 
are particularly high for patients with recurrent CDI due to the long duration of the disease, 
the costs involved in diagnosis, treatment, hospitalizations, and recurrent treatments.2 They 
also found that while the average cost of the first episode was $1,914, the average cost for 
subsequent episodes was $3,103 totaling on average to $10,970 for patients with multiple 
episodes. Kyne et al. performed an analysis of CDI-attributable costs using a cohort study 
design and found it to be $3,669 (95% confidence interval [CI] $1,126 to $7,024) per 
episode. Another recent study using a retrospective cohort study design found that CDI 
was associated with excess costs of $3,240 (P < 0.001; increase in cost, 33%) and with 
$5,042 (95% CI $3,797 to $6,481; increase in cost, 53%) attributable inpatient costs over 
180 days.11 
 
Risk Factors for CDI 
Major risk factors for CDI include antibiotic exposure, hospitalization or admission 
to a long-term care facility, and advanced age.52, 53 Other risk factors of recurrent CDI are 
increasing age, increased severity of underlying disease, and low serum antibody response 
to toxin A.45,53 The use of gastric acid-inhibitors, especially proton pump inhibitors (PPI), 
has also been proposed as a possible risk factor.54 In a recent case-control study by Aseeri 
et al. in 2008, PPI use was associated with an increased risk of CDI (OR = 3.6, 95% CI 1.7 
to 8.3; P < 0.001).55 
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C. difficile spores can be transmitted through the fecal-oral route in the public; 
however, the spores are more prevalent in hospital and long-term care facilities. 
Transmission can occur through infected patients, contaminated surfaces in hospitals, or 
through personnel whose hands are contaminated by the bacteria.45 In general, exposure to 
the healthcare setting also increases the risk of developing CDI. Within the hospital setting, 
patients admitted to an intensive care unit and those having a prolonged hospital stay are 
more likely to become infected with C. difficile.53 
Exposure to almost any antibiotic can predispose a patient to a C. difficile infection. 
Historically, it is known that clindamycin, cephalosporins, and certain broad spectrum 
penicillins were most commonly associated with CDI.53 Although most of the published 
literature identifies antibiotic use and hospitalization as the primary risk factors for CDI, 
there is some evidence to the contrary. A recent review article by Thomas et al. identifies 
several biases in articles reporting a relation between antibiotic use and CDI;56 while a 
study by Wilcox found that only 50% of C. difficile cases had taken antibiotics in the 
previous month and only 32% had been hospitalized in the previous 6 months. 
Advanced age also has been found to be a significant risk factor for the CDI. 
Patients older than 65 years have more than 15-fold greater chance of developing CDI 
compared with younger patients.12, 57 Immunosuppressant and chemotherapy have also 
described as risk factors for CDI; however, this hypothesis has been questioned by 
others.53 
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Diagnosis of CDI 
The diagnosis of CDI is generally based on the detection of C. difficile toxins (A, 
B, or both) in the stool. Usually only symptomatic patients are tested using diarrheal stool 
specimens as there is no value of testing stool samples of asymptomatic patients unless an 
outbreak is being investigated.45 Culture of the stool for the C. difficile bacteria is another 
sensitive test; however, not all C. difficile strains produce toxin and the test may be 
positive for a non-toxicogenic strain. This test is not used routinely except in some 
research studies since it may require 48 hours for a culture to become positive.59 
Tissue culture assay for cytotoxicity of toxin B is considered the “gold standard” 
for diagnosing CDI with a sensitivity of around 80%-100% and a specificity of 99%. 
Because of the sensitivity of the test, it is not usually necessary to test multiple stool 
samples.45, 47, 59 
Many clinical laboratories use the enzyme-linked immunosorbent assay (ELISA) 
method, which can be performed more quickly than culture assay, usually within hours. 
This assay can detect either toxin A or B in stool and is very specific but less sensitive. 
This essay has been reported to have false-negative rate of up to 40%; however, it has the 
ability to identify cases of toxin A negative/toxin B positive. 45, 60, 61 Polymerase chain 
reaction test is another method for diagnosis of CDI and has been reported to have a very 
high sensitivity but poor specificity due to difficulty in distinguishing between asymptotic 
carriage and symptomatic infection.47, 62 
Direct endoscopic visualization of the colonic mucosa can be useful in making the 
diagnosis of CDI. To avoid possible colonic perforation with this technique, it has been 
15 
 
reserved for patients with severe disease and negative laboratory results for rapid 
diagnosis.47, 59 
 
Standard Treatment of CDI 
Current treatment strategies of CDI consist of discontinuing, if possible, the 
offending antibiotic. This is sufficient for mild cases of the disease. For more severe cases, 
CDI is normally treated with oral metronidazole (250 mg four times a day or 500 mg three 
times a day for 10-14 days) or oral vancomycin (125 mg four times a day for 10-14 days). 
For severe cases, oral vancomycin is recommended as the first line therapy. Finally, for 
severe CDI cases with complication, vancomycin 500 mg orally or via nasogastric tube 4 
times per day and/or intravenous metronidazole 500–750 mg every 8 hours is 
recommended.45 In moderate cases metronidazole is the preferred initial choice because of 
its low price and to reduce the use of vancomycin to avoid increased resistance of 
Enterococci species.45 These treatment strategies are associated with a recurrence rate of 
up to 28% in patients 3 to 28 days after the antibiotic has been discontinued.6, 12 Some 
evidence shows that oral teicoplanin, which is not available in the United States, may be a 
better choice than vancomycin in some cases.13 For patients not responding to antibiotics, 
surgical intervention may be required when colonic perforation or toxic megacolon is 
suspected.45 
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Probiotics 
Probiotics, defined as live microbial dietary supplements that beneficially affect the 
host by improving intestinal microbial balance,15 have been used as a way of restoring 
intestinal microflora. This acts as a protective barrier that resists the colonization of 
intestinal pathogens and consequently decreases the incidence and duration of AAD in 
general. Probiotics may also prevent and treat CDI. They are relatively inexpensive, 
generally safe, and well tolerated.16 There are different types of probiotics that have been 
used for the prevention and treatment of CDI, including various strains of Lactobacillus 
(Lactobacillus GG, Lactobacillus rhamnosus, Lactobacillus casei, and Lactobacillus 
plantarum 299v) and the yeast Saccharomyces (Saccharomyces boulardi and 
Saccharomyces cerevisiae). Lactobacillus GG and Saccharomyces boulardii were shown 
to be more effective and more commonly used than other probiotics.63, 64 In addition, 
probiotics have many other potential positive health effects.24, 27, 28 
 
Mechanism of Action 
As mentioned before, disturbance of the normal colonic flora prompts colonization 
of C. difficile.45 Probiotics may prevent or treat the colonization by pathogens through 
restoring the equilibrium in the altered gastrointestinal normal flora.65 Several potential 
mechanisms of action have been suggested by which probiotics can promote 
gastrointestinal health. Probiotics competitively inhibit pathogen adherence to colonic 
epithelial and mucosal cells. This keeps the tight junction proteins intact and prevents both 
uptake of intact macromolecules and translocation of organisms to the mesenteric lymph 
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nodes. Also, probiotics can enhance production and secretion of anti-inflammatory 
cytokines, including interleukin-10. Stimulation of secretory immunoglobin A and other 
immunoglobins by the immune system is another proposed mechanism of action.66 In 
addition, probiotics may enzymatically modify toxin receptors and compete with 
pathogens for nutrients.45, 56, 67 
 
Pharmacokinetics of Probiotics 
The beneficial effects of probiotics depend on their ability to protect the active 
constituents, such as enzymes, against gastric acidity and deliver them to the colon. The 
survival of probiotics in the gastrointestinal tract differs widely depending on their intrinsic 
resistance, host factors, and the formulation used, Figure 2.4.68 
Pharmacokinetic studies of S. boulardii and Lactobacillus acidophilus in healthy 
volunteers have shown that it reaches steady state levels of 1 × 108 colony-forming units 
(CFU)/gram after three days of oral dosing with 0.5gram (1 × 1010 CFU/g) twice a day.69 
The amount of probiotics in the colon declines rapidly after cessation of dosing. 
As part of a randomized study on S. boulardii for the treatment of recurrent CDI, 
Elmer et al. measured S. boulardii concentrations at various times in the stool samples of 
patients. Patients in the intervention group received 1gram of lyophilized S. boulardii per 
day containing about 10 × 109 CFUs along with either vancomycin or metronidazole. Of 
the 50 intervention group patients, 41 (82%) had detectable stool concentrations of S. 
boulardii ranging from 1.5 × 103 to 6.2 × 107 CFUs per gram. Furthermore, they found S. 
boulardii concentrations were higher in patients who did not have a recurrence of CDI (1 × 
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106 CFU per gram compared to 1.5 × 104 CFU per gram). These differences were not 
explained by age, gender, or antibiotic type/dose. The same study found that S. boulardii 
was cleared by 94% of patients by the third day after treatment was discontinued.69 
 
 
 
 
Figure 2.3 – Classification of probiotics according to their resistance in the 
gastrointestinal tract  
Note: Some ingested probiotics are rapidly destroyed in the stomach (A), whereas others survive better 
beyond the stomach but are destroyed by bile (B) or by the endogenous flora (C). Some probiotics have a 
high survival through the gastro intestinal tract (D), close to that of a marker (M). (Source: Ref. 68) 
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Probiotics for Treatment of CDI  
There have been several studies reported in the last three decades looking at the 
effect of probiotics, including Lactobacillus spp and Saccharomyces spp on the treatment 
of CDI. 7, 8, 18-26, 63, 64 These studies may have shown contradictory results because of 
insufficient power to detect significant differences due to differences in the study 
population, type and dose of probiotics given, or the duration of treatment.18, 19 
In a letter to the Lancet in 1987, Gorbach et al. described the successful treatment 
of five patients with recurrent CDI using Lactobacillus GG. All patients (n = 5) had 
multiple recurrences within a 10-day period after antibiotic therapy. Following treatment 
with Lactobacillus GG there was no recurrence for periods ranging from four months to 
four years.72 A study by Surawicz et al. reported cessation of CDI in 11/13 (84.6%) 
patients treated with S. boulardii.23 Kimmey et al published a case report of a 67-year-old 
woman using S. boulardii to treat and prevent recurrent CDI. Over 8 months the patient 
experienced 8 CDI recurrences. The patient was treated with a 4 week course of 
vancomycin. After failing to resolve the diarrhea, S. boulardii was added with another 
vancomycin regimen until semi-formed stools developed. She took the probiotic for total 
of about 90 days.73 
In a case study, Pakyz reported a use of Lactobacillus in the treatment of a 
recurrent CDI case in an 87-year-old resident of a long-term care facility. Two weeks after 
discharge from a hospital, the patient was readmitted for altered mental status, fever, and 
diarrhea. The patient was positive for C. difficile stool culture so she was placed on oral 
metronidazole and Lactobacillus. After five days of therapy, patient showed no minimal 
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improvement in diarrheal symptoms and was switched to oral vancomycin and 
Lactobacillus. Symptoms of diarrhea disappeared after 14 days of therapy.74  
Table 2.2 summarizes six RCTs that evaluated the effect of different types of 
probiotics in the treatment of CDI or recurrent CDI. In a randomized, double-blind, 
placebo-controlled study, McFarland et al. studied 124 patients with active diarrhea and a 
positive result from at least one C. difficile assay (culture, toxin A, or toxin B) who were 
treated with vancomycin and/or metronidazole.24 The intervention group (n = 57) was 
randomly selected to receive a lyophilized 500mg capsule of S. boulardii twice daily and 
the control group (n = 67) to placebo for 4 weeks. Approximately half (n = 60) of the 
patients had at least one prior CDI. Patients were excluded if they had AIDS or if they 
were immunosuppressed secondary to chemotherapy within the past three months. CDI 
recurrence rates were calculated for 4 weeks after discontinuing the S. boulardii. Overall 
the treatment failure rate was 26.3% in the S. boulardii group versus 44.8% in the placebo 
group (P = 0.05). In the patients with history of CDI, 34.6% of the treatment group failed 
therapy versus 64.7% of placebo patients (P = 0.04). Compared to the control, those in the 
treatment group were significantly more likely to experience cessation of diarrhea 
(Relative Risk [RR] = 1.33; 95% CI 1.02 to 1.74) and were significantly less likely to 
experience recurrence of diarrhea after cessation of antibiotic therapy (RR = 0.59; 95% CI 
0.35 to 0.98). Although the treatment group was small, these results suggested that patients 
experiencing at least one recurrent episode of CDI may benefit from S. boulardii treatment. 
The main conclusion of the authors was that there was a statistically significant beneficial 
effect of S. boulardii on recurrent CDI, particularly among patients who have had at least 
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one prior episode of CDI. One of the limitations of this study was not accounting for 
severity of illness.50 
Surawicz et al. studied 168 adult patients with recurrent CDI, defined as one or 
more previous episodes of diarrhea that had a positive C. difficile assay and initial response 
to antibiotic treatment.22 Patients were divided into three treatment groups: high dose oral 
vancomycin (2 g/day; n = 32), oral low dose vancomycin (500 mg/day; n = 85), or oral 
metronidazole (1 g/day; n = 53), all for 10 day. The oral high dose vancomycin group was 
randomized to receive either S. boulardii 500 mg twice daily (n = 18) or placebo (n = 14) 
for 28 days starting on day 7 of the 10 day course of antibiotic. They were followed for a 
total of two months. No information about the other two groups was provided. In the high 
dose oral vancomycin treatment group, a 16.7% recurrence rate versus a 50% recurrence 
rate in the placebo group (P = 0.05; RR = 0.33; 95% CI 0.10 to 1.06). S. boulardii did not 
significantly decrease the recurrence rate in either the vancomycin 500 mg daily group or 
the metronidazole group. The authors concluded that there was a beneficial effect of S. 
boulardii in patients treated with high dose vancomycin even though this is in a small 
group of 32 patients. This was surprising, however, because these patients had more 
serious manifestations of CDI than other sub-groups and the confidence interval was very 
wide.22 
In 2003, Wullt et al. in a multi-center randomized double-blind placebo controlled 
study examined 21 adult patients with recurrent CDI. Patients were included if they had 
ongoing diarrhea and a positive C. difficile toxin assay within six days of enrollment or if 
they had CDI within the previous two months and were not being treated with a list of 
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drugs including vancomycin and metronidazole at the time of enrollment. Patients were 
randomized to receive oral metronidazole 400 mg three times daily for 10 days in 
combination with either fruit drink containing Lactobacillus plantarum 299v once daily (n 
= 12) or placebo (n = 9) for 38 days. A total of only 21 patients completed the study across 
the nine centers over the two-year period. No statistically significant differences between 
the two groups were seen in the cure rate of initial CDI (RR = 0.93; 95% CI 0.73 to 1.19), 
recurrence of CDI (RR = 0.55; 95% CI 0.22 to 1.35), or cure rate by stool assay (RR = 
0.75; 95% CI 0.41 to 1.36). The numbers of patients involved in this study were too small 
to allow any strong conclusions. The authors’ concluded that probiotics either counteract 
the pathogenesis of C. difficile or have a positive overall impact on the microflora that 
prevents clinical recurrence; however, they did not provide any results to support that 
conclusion.26 
Lawrence et al. conducted a randomized double-blind placebo controlled pilot 
study in a total of 15 adult patients with recurrent CDI. Patients were included if they had 
ongoing diarrhea and a positive C. difficile toxin assay and history of CDI in the preceding 
year. Exclusion criteria included critical or terminal illness, compromised immunity, more 
than five days of CDI treatment, and recent probiotic use. Patients were randomized to 
receive either 40 mg lyophilized Lactobacillus GG twice daily (n = 8) or placebo (n = 7) 
for 28 days in addition to the CDI treatment and were followed for 60 days. A total of three 
(37.5 %) cases of RCDI were observed in the Lactobacillus arm and one (14.3 %) in the 
placebo arm (RR = 2.6; 95 % CI 0.3 to 19.9). No conclusion was provided since the study 
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was not powered to detect a difference in outcomes for interest; that also resulted in a very 
wide confidence interval. The study was well designed but had a very small sample size.30 
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Table 2.2 – Description of reviewed studies 
 
Study 
No. and Type 
of Subjects Probiotic 
Probiotic 
Dose / Day 
Treatment 
Duration 
Follow-
Up 
Probiotic-Treated 
Group Control Group  
Cured (%) Failed Cured (%) Failed 
McFarland LV 
1994 
124 Adults with 
CDI or RCDI  SB + V/M  2 × 10
10
  4 wk  4 wk  42 (73.68) 15  37 (55.22) 30  
Surawicz CM 
2000  
32 Adults with 
RCDI  SB + V  2 × 10
10
  4 wk  4 wk  15 (83.33) 3  7 (50.00) 7  
Pochapin M 
2000  
25 Adults with 
CDI or RCDI 
LGG + V 
or M  N/R  3 wk  0  7 (63.63) 4  9 (64.28) 5  
Wullt M 
2003  
20 Adults with 
RCDI 
LP 299v + 
M  5 × 10
10
  38 days  0  7 (63.63) 4  3 (33.33) 6  
Plummer S 
2004  
138 Inpatients 
varied ages 
LABB, no 
V or M  2 × 10
10
  20 days  0  67 (97.10) 2  63 (91.30) 6  
Lawrence SJ 
2005  
15 Adults with 
RCDI 
LGG + V 
or M  6 × 10
11
  3 wk  4 wk  5 (62.50) 3  6 (85.71) 1  
CDI: Clostridium difficile infection; RCDI: Recurrent Clostridium difficile infection; SB: Saccharomyces boulardii; LGG: Lactobacillus rhamnosus GG; 
LP: Lactobacillus plantarum 299v; V: Vancomycin; M:  Metronidazole, LABB =Lactobacillus acidophilus and Bifidobacterium bifidum;N/R: Not 
reported. (Source: Reference 18) 
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A meta-analysis by McFarland compared the efficacy of probiotics for the 
treatment of CDI based on the published RCTs (n = 6) in adult hospitalized patients, Table 
2.2. This meta-analysis concluded that probiotic therapy is effective in the treatment of 
CDI. The pooled relative risk (Figure 2.4) for CDI associated with probiotic use from the 
six RCTs included was 0.59 (95% CI 0.41 to 0.85). The heterogeneity of the included 
studies was not significant; however, the relatively small number of trials included could 
be a limiting factor in this meta-analysis.18 
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Figure 2.4 – Forest Plot of six randomized controlled trials of probiotics for the 
treatment of Clostridium difficile Infection. (Source: Ref. 18) 
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CHAPTER 3 METHODOLOGY 
 
 
Data Source 
The data used in this study were obtained from the Clinical Resource Manager 
(CRM) program developed and maintained by the University HealthSystem Consortium 
(UHC; www.uhc.edu). UHC is an alliance of 102 academic medical centers representing 
approximately 90% of the nation’s non-profit academic medical centers. UHC provides 
programs and services to improve clinical, operational, and patient safety performance.75 
The CRM database program brings together data from a subset of participating hospitals, 
with the actual number of hospitals in the database varying by the year. The information in 
the database is obtained from various sources including patient encounters, billing 
information, transactional data, as well as discharge summaries to provide standardized 
information on in-hospital resource utilization and patient outcomes.76 The drug use data in 
the CRM has been previously validated.77 
 
Study Design 
The study was composed of two general parts: descriptive and analytical. First, the 
demographic and clinical characteristics of Lactobacillus users and non-users were 
described (Specific Aim 1) using cross sectional study design. Among probiotic users, the 
initiation date of probiotics was described with respect to the initial antibiotic therapy 
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initiation date (Specific Aim 2) and CDI treatment initiation date (Specific Aim 3). The 
second part of this study is a retrospective cohort study (Specific Aim 4). A cohort of all 
nosocomial CDI patients in the CRM database was reviewed for certain CDI-related 
outcomes of interest. The relationship between the use of Lactobacillus and switch rate of 
CDI treatment, readmission for CDI, mortality, and post-CDI-diagnosis length of stay were 
examined. This study was approved by the Institutional Review Board at Virginia 
Commonwealth University.  
 
Study Sample 
The data for this project were derived from a separate study designed to examine 
the risk of CDI associated with various antibiotic agents.9 It examined all patients having 
an ICD-9-CM code for CDI (008.45) and two controls for each case. Controls were 
randomly drawn from the same hospital and quarter of discharge as the cases. 
Lactobacillus may be considered a non-formulary agent at some institutions. This can 
result in unreported usage of the agent. Only those hospitals reporting Lactobacillus usage 
were included in this study. For the current study, data were obtained from hospitals 
participating in the CRM during the period from July 1, 2003, to December 31, 2005, 
representing 2.5 years in the study period. The analysis was limited to that period because 
it has relatively high number hospitals who consistently report Lactobacillus use and large 
number of CDI patients. The data included the following information for each patient: 
demographic characteristics, detailed antibiotics use (e.g., name, start date, end date, and 
length of therapy ), admission and discharge dates, total length of stay, the All Patients 
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Refined-Diagnosis Related Group (APR-DRG) severity of illness category,78 and all 
discharge diagnosis codes. All data were obtained directly from UHC. 
Patients included in the analysis were 18 years of age or older and discharged from 
one of the participating hospitals during the study period. Based on unique patient 
identification numbers and admission dates, cases of recurrent CDI (readmission) were 
able to be identified. 
 
Analysis Variables 
For the first part of the study, users and non-users of Lactobacillus were described 
with respect to various patient demographic characteristics, CDI status (i.e., no CDI, 
nosocomial CDI, and non-nosocomial CDI). Lactobacillus users were also described with 
respect to when Lactobacillus was started in relation to antibiotic therapy and CDI 
treatment. Post-CDI-diagnosis length of stay, switch rate of CDI treatment (i.e., switching 
from vancomycin to metronidazole or vice versa), readmission for CDI, and mortality, are 
the outcome variables for the second phase. 
The primary independent variable of interest for the models in the second part of 
the study was the use of Lactobacillus. Many potential confounding variables were 
included in the analysis. These included sex, race, transfer from outside hospital status, 
switch of CDI treatment status, severity of illness, comorbidity, and mortality.  
Comorbidity was measured using the Dartmouth-Manitoba version of the Charlson 
Comorbidity Index (DM-CCI), which is an adaptation of the original Charlson 
Comorbidity Index (CCI) to utilize the ICD-9-CM codes from administrative data.58, 79 The 
30 
 
CCI is a list of 19 medical conditions which were selected and weighted based on the 
strength of their association with mortality. The comorbidity score is the total sum of 
weights assigned to each condition. The DM-CCI was selected as a measure of 
comorbidity because it is based on an ICD-9-CM coding system, which is the same coding 
system used in our database. DM-CCI has been validated in a study, by Ghali et al. 
comparing it two other comorbidity indexes.17 
 
Methods 
As mentioned previously, this study has two general parts: a descriptive part 
(Specific Aims 1-3) and an analytical part (Specific Aim 4). Throughout the study CDI 
cases are described as nosocomial or non-nosocomial. The nosocomial cases must meet 
two criteria, the ICD-9-CM code for CDI and starting CDI treatment (metronidazole or 
vancomycin) on or after day five of hospitalization. Those CDI cases starting treatment 
before day five were considered non-nosocomial cases.77 Based on prior research, 
switching of CDI treatment, readmission for CDI, mortality, and length of stay were 
selected as the outcomes of interest. These variables are not only represent the morbidity 
and mortality of patients but also measure the impact of CDI to healthcare system. The 
exposure variable of interest is the use of a blend of Lactobacillus acidophilus and 
Lactobacillus helveticus (Lactinex®). 
For the first aim, all patients receiving Lactobacillus were compared to those not 
receiving Lactobacillus. The demographic characteristics (age, gender, and race) and the 
clinical characteristics (CDI status, number of antibiotics received, transfer status, severity 
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of illness, mortality, readmission, and overall length of stay) were described. Analytical 
weights were used in this descriptive piece to take into account the way in which the 
controls were sampled. These weights are described in the next section. The top 5 ICD-9-
CM discharge diagnosis codes for Lactobacillus users and non-users in the total sample, 
CDI cases (both nosocomial and non-nosocomial), and non-CDI cases were identified. The 
number and percentage of patients who had the code and the description of the code were 
reported. Also, the distribution of antibiotics used by study patients was described. 
Antibiotics were classified into seventeen different classes or individual drugs: penicillins, 
penicillinase-resistant penicillins, broad spectrum penicillins, 1st generation 
cephalosporins, 2nd generation cephalosporins, 3rd and 4th generation cephalosporins, 
carbapenems, aminoglycosides, fluoroquinolones, macrolides, tetracyclines, 
trimethoprim/sulfamethoxazole, other sulfonamides, clindamycin, vancomycin, 
metronidazole, and miscellaneous antibiotics. The specific agents in each class are 
provided in Table 3.1. For each class of antibiotics the frequency and percentage were 
reported. 
32 
 
Table 3.1 – Antibiotic agent classifications 
 
Antibiotic class Antibiotic agents 
Penicillins Penicillin G, penicillin V, amoxicillin, amoxicillin/clavulanate 
potassium, ampicillin, ampicillin/sulbactam 
 
Penicillinase-
resistant penicillins 
Cloxacillin, dicloxacillin, methicillin, nafcillin, oxacillin 
 
Extended-spectrum 
penicillins 
Carbenicillin disodium, carbenicillin indanyl sodium, mezlocillin, 
piperacillin, ticarcillin, ticarcillin/clavulanate, 
piperacillin/tazobactam 
 
1st generation 
cephalosporins 
Cefadroxil, cefazolin, cephalexin, cephalothin, cephapirin, 
cephradine 
 
2nd generation 
cephalosporins 
Cefaclor, cefprozil, cefonicid, cefotetan,cefoxitin, cefuroxime, 
loracarbef, cefditoren, cefamanadole 
 
3rd and 4th 
generation 
cephalosporins 
Cefixime, cefoperazone, cefotaxime, ceftazidime, ceftizoxime, 
cefpodoxime, ceftriaxone, cefmetazole, cefdinir, ceftibuten, 
cefepime 
 
Carbapenems Imipenem/cilastatin, ertapenem, meropenem 
 
Aminoglycosides Amikacin, gentamicin, kanamycin, netilmicin, streptomycin 
sulfate, tobramycin, neomycin 
 
Fluoroquinolones Lomefloxacin, norfloxacin , ofloxacin, moxifloxacin, gatifloxacin, 
ciprofloxacin, levofloxacin, sparfloxacin, trovafloxacin 
 
Macrolides Azithromycin dehydrate, clarithromycin, erythromycin, 
troleandomycin, dirithromycin 
 
Sulfonamide 
combinations 
Sulfamethoxazole/trimethoprim 
Other sulfonamides Sulfadiazine, sulfamethoxazole, sulfasalazine, sulfisoxazole 
 
Tetracyclines Demeclocycline, doxycycline hyclate, minocycline, 
oxytetracycline, tetracycline  
 
 (cont.) 
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Table 3.1 (continued)   
    
Lincosamides Clindamycin 
 
Glycopeptides Vancomycin 
 
Imidazoles Metronidazole 
 
Miscellaneous 
antibiotics 
Aztreonam, colistimethate, methenamine hippurate, methenamine 
mandelate, metronidazole, moxalactam, polymyxin b sulfate, 
spectinomycin, trimethoprim, vancomycin, bacitracin, linezolid, 
daptomycin, fosfomycin, trimetrexate glucuronate, 
quinupristin/dalfopristin, chloramphenicol, tigecycline, 
telithromycin, furazolidone, nitrofurantoin, nitrofurantoin, 
macrocrystals, rifaximin 
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For the second aim, the day on which Lactobacillus was initiated with respect to 
antibiotic therapy initiation dates were described among patients who were on antibiotics 
and Lactobacillus. The frequency and percentage of patients who started Lactobacillus at 
each initiation day were reported.  The percentages were also reported by CDI status. 
For the third aim, the day Lactobacillus was initiated with respect to CDI 
treatment initiation dates were described among CDI patients who were using 
Lactobacillus. The frequency and percentage of patients who started Lactobacillus at each 
initiation day were reported. The percentages were also reported by CDI status. 
For the fourth aim, the sample included all nosocomial CDI patients and the 
exposure variable of interest is Lactobacillus use. The crude (un-adjusted) relationship 
between Lactobacillus use and the following CDI related outcomes were calculated: switch 
rate of CDI treatment, readmission for CDI, mortality, and post-CDI-diagnosis length of 
stay. The adjusted relationships between Lactobacillus use and the same outcomes of 
interest were examined and reported while adjusting for various potential confounders, 
such as age, sex, race, transfer from outside hospital status, switch of CDI treatment status, 
severity of illness, intensive care unit (ICU) days, Charlson score, and mortality. 
Comorbidity and other potential confounding variables were accounted for in the analysis 
for more accurate assessment of the relationship. For assessment of crude and adjusted 
relationship between Lactobacillus use and switch rate of CDI treatment only those who 
used Lactobacillus before diagnosis were considered in the analysis 
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Statistical Analysis 
Descriptive statistics including the mean and standard deviation or median and 25th 
and 75th percentiles for continuous variable or proportion with 95% confidence intervals 
for categorical variables were calculated for all demographic and clinical characteristics 
measured. For the comparison of continuous variables that were approximately normally 
distributed, the Student’s t-test was used. For non-normally distributed variables, the 
Wilcoxon rank sum test was used. Fisher’s exact test was used for categorical data. The 
relationship between Lactobacillus use and each of categorical outcome variables (switch 
rate of CDI treatment, readmission for CDI, and mortality) were examined with a multiple 
logistic regression model. A linear regression model was built for the examination of the 
relationship between Lactobacillus use and length of stay. Odds ratios from the logistic 
regression model and their 95% confidence intervals were reported for all categorical 
variables. From the linear regression model, the regression coefficients and 95% 
confidence intervals were reported. All potential confounders were accounted for in the 
data analysis to assure a more accurate assessment of the relationship between 
Lactobacillus and the selected outcome variables. For all analyses, statistical significance 
was determined using two sided Type I error level of 5%. Statistical analyses were 
conducted using Stata/SE version 10.0 (Stata Corporation, College Station, TX). 
 In the original dataset, all patients with an ICD-9-CM code for CDI were obtained 
from the CRM database within the study period. The non-CDI patients were sampled so 
that there were two of these non-CDI drawn from the same quarter and hospital as each 
CDI patient. To account for this random sampling approach, a set of analytical weights 
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were derived. These weights are equal to the inverse of the probability of being sampled. 
Since all patients with a CDI diagnosis code were sampled, their weight was equal to 1. 
For the controls, the weights were equal to the inverse of twice number of cases identified 
for a given hospital and quarter divided by the total number of discharges for that quarter 
less twice the number of cases. This weight can be represented as shown in the following 
equation where wi is the weight for patient i, cj is the number of cases from hospital j, and 
dj is the number of adult discharges for hospital j.  
1
2
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j j
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These weights were applied when performing the descriptive analysis for Specific Aim 1. 
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CHAPTER 4: RESULTS 
 
 
Hospital Characteristics 
A description of the general characteristics of participating hospitals in the study 
sample are presented in Tables 4.1 and 4.2. The data used in this study represent 31 
teaching hospitals from six different regions throughout the nation. About half of the 
hospitals were from the Midwestern or Southeastern region (22.58% each). The other half 
were mainly from Mid-Atlantic or Mid-Continent regions (19.35% each). Only two 
hospitals were from New England region, 6.45%. The capacity of these hospitals range 
from 156 to 805 beds (mean = 513.97, SD = 153.57). About 70% of the hospitals have a 
capacity range from 300 to 600 beds. All of the participating hospitals had a case mix 
index (CMI) over one ranging from 1.46 to 2.13, (mean = 1.81, SD = 0.16). That means 
these hospitals treat sicker patients and therefore, their adjusted cost per patient or per day 
is more than the average reimbursement by Medicaid.14 
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Table 4.1 – Hospital characteristics 
 
Hospital Characteristic 
No. 
Hospitals (%) 
Region  
Midwestern 7 (22.58%) 
Southeastern 7 (22.58%) 
Mid-Atlantic 6 (19.35%) 
Mid-Continent 6 (19.35%) 
Western 3 (9.68%) 
New England 2 (6.45%) 
Bed size category  
1 to 199 1 (3.23%) 
200 to 299 0 (0.00%) 
300 to 499 12 (38.71%) 
500 to 599 10 (32.26%) 
600 to 699 4 (12.90%) 
More than 700 4 (12.90%) 
Bed size  
Mean (SD) 513.97 (153.57) 
Median (25th, 75th percentile) 533 (396, 614) 
Case mix index  
Mean (SD) 1.81 (0.16) 
Median (25th, 75th percentile) 1.83 (1.68, 1.92) 
SD: standard deviation 
 
 
 
Study Population 
The total population of this study, as shown in figure 4.1, was 35,670 patients. The 
cases were 8,968 (25%) and the remaining 26,703 (75%) were controls who had no CDI. 
Almost half of the cases were non-nosocomial cases 4,428 (12%) and the other half were 
nosocomial cases 4,540 (13%). There were 480 Lactobacillus users majority of them had 
CDI (237 (49%) had non-nosocomial CDI and 202 (42%) had nosocomial CDI). After 
applying the weight there were 2,564 Lactobacillus users majority had no CDI (Figure 
4.2).  
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Figure 4.1 – CDI status in overall study sample 
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Figure 4.2 – CDI status within Lactobacillus users [weighted percentages] 
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Patients Demographic and Clinical Characteristics 
Of the 480 Lactobacillus users, 439 had CDI (237 (54%) had non-nosocomial CDI 
and 202 (46%) had nosocomial CDI). The average duration of use was not significantly 
different among non-nosocomial and nosocomial cases, 9.55 days (SD = 16.66) and 11.29 
days (SD = 18.10), respectively (Table 4.2). 
The unweighted and weighted detailed description of the demographic and clinical 
characteristics of Lactobacillus users and non-users are listed below (Table 4.3 and Table 
4.4, respectively). Users of Lactobacillus were significantly older that non-users with 
average ages of about 61.1 years (SD = 18.5) and 53.8 years (SD = 18.98), respectively. 
Both groups were almost equally distributed between male and female. The majority of 
both groups were Caucasian or African American. Among Lactobacillus users, 375 
(78.13%) were Caucasian and 54 (11.25%) were African American. In the non-users, 
21,806 (61.97%) were Caucasian and 7,597 (21.59%) were African American. There were 
no big differences in race distribution after applying the weight. Also, almost all 
Lactobacillus users 439 (91.46%).had CDI with 237 (49.38%) users having non-
nosocomial CDI and 202 (42.08%) having nosocomial CDI. Of the non-users there were 
4,191 (11.91%) non-nosocomial CDI cases and 4,338 (12.33%) nosocomial CDI cases 
(Table 4.3 and Figures 4.3). Patents with no CDI [2,125 (82.88%)] were the majority after 
applying the weights (Table 4.4 and Figure 4.4). With respect to the number of antibiotics 
received, over 60% of the Lactobacillus users had four or more antibiotics. In the non-
users, almost 28% received no antibiotics and almost 25% received only one antibiotic 
(Table 4.3 and Figure 4.5). After applying the analytical weights, the percentage of 
41 
 
Lactobacillus users who did not use any antibiotics increased from 0.42% to 7.53%, and 
those who used four or more antibiotics decreased from 61.88% to 55.38%. For non-users 
the percentage of those who did not use any antibiotics increased from 27.68% to 36.38% 
and those who used four or more antibiotics decreased from 19.47% to 8.15% (Table 4.4 
and Figure 4.6). A majority of the users had an APR-DRG severity of illness category of 
major (35.83%) or extreme (53.33%). Oppositely, the non-users were mainly minor 
(24.97%) or major (33.25%) severity of illness category (Table 4.3 and Figure 4.7). After 
applying the analytical weights, the percentage of users who were moderately ill increased 
from 10.42% to 22.12% and those who were extremely ill decreased from 53.33% to 
45.16%. For non-users the percentage those who were moderately ill increased from 
24.97% to 32.37% and those who were extremely ill decreased from 15.72% to 6.37% 
(Table 4.4 and Figure 4.8). Unlike the non-users, almost one third of Lactobacillus users 
were readmitted for CDI. The average length of stay was significantly higher for users 
(mean = 27.64, SD = 39.07; median = 17) than non-users (mean = 8.63, SD = 13.71; 
median = 4) (P <0.001). After applying the analytical weights, the mean length of stay for 
both users and non-users decreased from 27.64 days to 24.53 days and from 8.63 days to 
5.44 days; respectively. Generally, there were minor differences between weighted and 
um-weighted statistics. 
There was small missing data (2.85%) in the race variable which was added to the 
“other” category. Also, there was negligible missing data (< 0.01%) in the gender variable. 
Other variables have no missing data. Three observations were dropped because their 
diagnosis dates were after their discharge dates. 
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Table 4.2 – Description of Lactobacillus usage by CDI patients  
 
Lactobacillus Usage Non-nosocomial CDI Nosocomial CDI P-value 
Count (%) 237 (53.99) 202 (46.01)  
Mean (SD) 9.55 (16.66) 11.29 (18.10) 0.2965 
Median (25th, 75th percentile) 6 (2, 11) 6 (3, 12) 0.2276 
SD: Standard deviation; CDI: Clostridium difficile infection. 
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Table 4.3 – Patient demographic and clinical characteristic of Lactobacillus users and 
non-users [Unweighted statistics] 
 
Variables 
Lactobacillus  
P-value  Usersa  (n = 480) Non-usersb (n = 35,190) 
Age in years [Mean (SD)] 61.09 (18.15) 53.78 (18.98) < 0.001 
Genderc [No. (%)]   0.166 
Male 248 (51.67%) 19,294 (54.83%)  
Female 232 (48.33%) 15,892 (45.16%)  
Race [No. (%)]   < 0.001 
Caucasian 375 (78.13%) 21,806 (61.97%)  
African American 54 (11.25%) 7,597 (21.59%)  
Hispanic 23 (4.79%) 2,415 (6.86%)  
American Indian/Eskimo 1 (0.21%) 170 (0.48%)  
Asian 3 (0.63%) 550 (1.56%)  
Other 12 (2.50%) 1,646 (4.68%)  
Unknown 12 (2.50%) 1,006 (2.86%)  
CDI status [No. (%)]   < 0.001 
No CDI 41 (8.54%) 26,661 (75.76%)  
Non-nosocomial CDI 237 (49.38%) 4,191 (11.91%)  
Nosocomial CDI 202 (42.08%) 4,338 (12.33%)  
Number of antibiotics 
received [No. (%)] 
  < 0.001 
None 2 (0.42%) 9,741 (27.68%)  
One 35 (7.29%) 8,679 (24.66%)  
Two 60 (12.50%) 5,929 (16.85%)  
Three 86 (17.92%) 3,988 (11.33%)  
Four or more 297 (61.88%) 6,853 (19.47%)  
Transferred from an outside 
hospital [No. (%)] 
  < 0.001 
No 458 (95.42%) 34,984 (99.41%)  
Yes 22 (4.58%) 206 (0.59%)  
Severity of Illnessd [No. (%)]   < 0.001 
Minor 2 (0.42%) 8,788 (24.97%)  
Moderate 50 (10.42%) 11,701 (33.25%)  
Major 172 (35.83%) 9,162 (26.04%)  
Extreme 256 (53.33%) 5,533 (15.72%)  
   (cont.) 
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Table 4.4 (continued)    
            
Mortality [No. (%)]   < 0.001 
No 438 (91.25%) 33,826 (96.12%)  
Yes 42 (8.75%) 1,364 (3.88%)  
Readmission [No. (%)]   < 0.001 
No 345 (71.88%) 31,890 (90.62%)  
Yes 135 (28.13%) 3,300 (9.38%)  
Length of staye     
Mean (SD) 27.64 (39.07) 8.63 (13.71) <0.001 
Median (25th, 75th 
percentile) 
17 (9, 32) 4 (2, 9) <0.001 
SD: Standard deviation; CDI: Clostridium difficile infection. 
aAll probiotics users; bAll probiotics non-users; cThere are four non-users with unknown gender; dThere were 
six non-users with no severity of illness specified; eOverall length of stay. 
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Table 4.4 – Patient demographic and clinical characteristic of Lactobacillus users and 
non-users [Weighted statistics] 
 
Variables 
Lactobacillus  
P-value  Usersa  (n = 2,500) Non-usersb (n = 1,386,538) 
Age-year [Mean (SD)] 58.92 (18.85) 51.88 (18.99) < 0.001 
Gender c [No. (%)]   0.2130 
Male 1404 (54.74%) 600,000 (43.21%)  
Female 1161 (45.26%) 790,000 (56.79%)  
Race [No. (%)]   0.0011 
White 2188 (85.30%) 850,000 (61.67%)  
African American 235.9 (9.20%) 290,000 (20.87%)  
Hispanic 70.84 (2.76%) 110,000 (7.82%)  
American Indian/Eskimo 1 (0.04%) 8,332 (0.60%)  
Asian 3 (0.12%) 22,000 (1.61%)  
Other 53.74 (2.10%) 65,000 (4.70%)  
Unknown 12 (0.47%) 38,000 (2.73%)  
CDI status [No. (%)]   < 0.001 
No CDI 2125 (82.88%) 1,400,000 (99.38%)  
Nosocomial CDI 237 (9.24%) 4191 (0.30%)  
Non-nosocomial CDI 202 (7.88%) 4338 (0.31%)  
Number of antibiotics 
received [No. (%)] 
  < 0.001 
None 193 (7.53%) 500,000 (36.38%)  
One 157.5 (6.14%) 410,000 (29.30%)  
Two 456.2 (17.79%) 240,000 (17.04%)  
Three 337.4 (13.16%) 130,000 (9.13%)  
Four or more 1420 (55.38%) 110,000 (8.15%)  
Transferred from an outside 
hospital [No. (%)] 
  < 0.001 
No 2542 (99.14%) 1,400,000 (99.98%)  
Yes 22 (0.86%) 206 (0.02%)  
Severity of Illness [No. (%)]   < 0.001 
Minor 2 (< 0.0018%) 450,000 (32.37%)  
Moderate 567.3 (22.12%) 550,000 (39.71%)  
Major 836.9 (32.64%) 300,000 (21.53%)  
Extreme 1158 (45.16%) 88,000 (6.37%)  
   (cont.) 
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Table 4.4 (continued)      
       
Mortality [No. (%)]   < 0.001 
No 2219 (86.52%) 1,400,000 (97.70%)  
Yes 345.6 (13.48%) 32,000 (2.30%)  
Readmission [No. (%)]   < 0.001 
No 2161(84.29%) 1,300,000 (95.79%)  
Yes 403 (15.71%) 58,000 (4.21%)  
Length of stay d     
Mean (SD) 24.53 (27.53) 5.44 (7.733) < 0.001 
Median (25th, 75th 
percentile) 
19 (7, 31) 3 (2, 6) <0.001 
SD: Standard deviation; CDI: Clostridium difficile infection. 
aAll estimated probiotics users; bAll estimated probiotics non-users; cThere are four missing observations 
with missing/unknown gender; dOverall length of stay. 
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Figure 4.3 – Unweighted CDI status of Lactobacillus users and non-users 
  
 
 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Users Non-users
No CDI Non-nosocomial CDI Nosocomial CDI Overall CDI
 
 
Figure 4.4 – Weighted CDI status of Lactobacillus users and non-users 
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Figure 4.5 – Unweighted number of antibiotics received by Lactobacillus users and 
non-users 
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Figure 4.6 – Weighted number of antibiotics received by Lactobacillus users and non-
users 
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Figure 4.7 – Unweighted severity of illness of Lactobacillus users and non-users 
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Figure 4.8 – Weighted severity of illness of Lactobacillus users and non-users 
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Top 5 Diagnoses Codes 
 In the total sample, CDI and unspecified essential hypertension were the first and 
second most frequent diagnosis codes among Lactobacillus users: 443 (7.0%) and149 
(2.4% ), respectively. The same codes, but in an alternate order, were the highest among 
non-users; 11,838 (3.7%) and 8,622 (2.8%). Other top 5 diagnosis codes for users and non-
users in the overall sample were listed in Table 4.5. 
In the CDI cases, CDI and unspecified essential hypertension, similar to the overall 
sample, were the first and second most frequent diagnosis codes among Lactobacillus 
users; 439 (7.5%) and 138 (2.8% ) respectively. Exactly the same diagnosis codes were 
also the highest among non-users: 11,838 (3.7%) and 8,622 (2.8%), respectively. Other top 
5 diagnosis codes for users and non-users among all CDI cases were listed in Table 4.6. 
CDI was the number one diagnosis in this group because the diagnosis code for CDI was 
used to identify CDI cases in participating hospitals for the original study. 
In the non-CDI patients, volume depletion was the most frequent diagnosis code 
among Lactobacillus users (12 [2.4%]). Among Lactobacillus non-users in the non-CDI 
patient, essential hypertension with no complications was the most frequent diagnosis code 
(8,953 [4.6%]). Other top 5 diagnosis codes for users and non-users in the overall sample 
are listed in Table 4.7. 
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Table 4.5 – Top 5 diagnoses ICD-9-CM codes for Lactobacillus users and non-users in 
the total sample 
 
Users codes  Non-users codes 
Diagnosis (code) 
No. 
(%)  Diagnosis (code) 
No. 
(%) 
Intestinal infection with 
Clostridium difficile (008.45) 
 
443 
(7.00) 
 Essential hypertension, unspecified 
(401.9) 
11,838 
(3.86) 
Essential hypertension, 
unspecified (401.9) 
 
149 
(2.35) 
 Intestinal infection with Clostridium 
difficile (008.45) 
8,622 
(2.81) 
Urinary tract infection, site not 
specified (599.0) 
 
144 
(2.27) 
 Diabetes mellitus (unspecified type) 
without complications not stated as 
uncontrolled (250.00) 
 
4,595 
(1.50) 
Volume depletion (276.5) 
 
118 
(1.86) 
 Coronary atherosclerosis of a native 
coronary artery (414.01) 
 
4,143 
(1.35) 
Congestive heart failure, 
unspecified (428.0) 
99 
(1.56) 
 Esophageal reflux (530.81) 3,916 
(1.28) 
CDI: Clostridium difficile infection; N: Number of patients who have the code;Users: Lactobacillus users; 
Non-users: Lactobacillus non-users; ICD-9-CM: The International classification of diseases, 9th revision, 
clinical modification;  
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Table 4.6 – Top 5 diagnoses ICD-9-CM codes for Lactobacillus users and non-users 
among CDI patients 
CDI: Clostridium difficile infection; N: Number of patients who have the code; Users: Lactobacillus users; 
Non-users: Lactobacillus non-users; ICD-9-CM: The International classification of diseases, 9th revision, 
clinical modification. 
 
 
 
Users codes  Non-users codes 
Diagnosis (code) 
No. 
(%)  Diagnosis (code) 
No. 
(%) 
Intestinal infection with 
Clostridium difficile (008.45) 
439 
(7.53) 
 Intestinal infection with Clostridium 
difficile (008.45) 
 
8,552 
(7.80) 
Essential hypertension,  
unspecified (401.9) 
138 
(2.37) 
 Essential hypertension, unspecified 
(401.9) 
 
2,885 
(2.63) 
Urinary tract infection, site not 
specified (599.0) 
 
134 
(2.30) 
 Urinary tract infection, site not 
specified (599.0) 
1,936 
(1.76) 
Volume depletion (276.5) 106 
(1.82) 
 Volume depletion (276.5) 
 
 
1,683 
(1.53) 
Congestive heart failure, 
unspecified (428.0) 
91 
(1.56) 
 Congestive heart failure, unspecified 
(428.0) 
1,517 
(1.38) 
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Table 4.7 – Top 5 diagnoses ICD-9-CM codes for Lactobacillus users and non-users 
among non-CDI patients 
Users  Non-users 
Diagnosis (code) 
No. 
(%)  Diagnosis (code) 
No. 
(%) 
Volume depletion (276.5) 12 
(2.40) 
 Essential hypertension with no 
complications (401.9) 
 
8,953 
(4.55) 
Essential hypertension with no 
complications (401.9) 
11 
(2.20) 
 Diabetes mellitus (unspecified type) 
without complications not stated as 
uncontrolled (250.00) 
 
3,352 
(1.70) 
Urinary tract infection, site not 
specified (599.0) 
 
10 
(2.00) 
 Coronary atherosclerosis of a native 
coronary artery (414.01) 
3,128 
(1.6) 
Acute renal failure, unspecified 
(584.9) 
 
9 
(1.80) 
 Tobacco use disorder (305.1) 3,125 
(1.59) 
Congestive heart failure, 
unspecified (428.0) 
8 
(1.60) 
 Esophageal reflux (530.81) 3,039 
(1.59) 
CDI: Clostridium difficile infection; N: Number of patients who have the code; Users: Lactobacillus users; 
Non-users: Lactobacillus non-users; ICD-9-CM: The International classification of diseases, 9th revision, 
clinical modification.  
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Distribution of Antibiotic Use in Lactobacillus Users 
Among antibiotic users, the frequency and percentage of those who were also on 
Lactobacillus and those who were not are described in Table 4.8 and Table 4.9. In the 
overall sample metronidazole (10,215 [28.64%]) and fluoroquinolones (9,532 [26.72%]), 
and 1st generation cephalosporins (8,883 [24.90%]) were the most commonly prescribed 
antibiotics. Other sulfonamides, tetracyclines, penicillinase-resistant penicillins were the 
least commonly prescribed antibiotics. After applying the weights (Table 4.9 and Figure 
4.10) 1st generation cephalosporins (370,000 [26.54%]), fluoroquinolones (250,000 
[18.16%]), and Penicillins (130,000 [9.58%]) were the most commonly prescribed 
antibiotics. 
Before applying the analytical weights (Table 4.8 and Figure 4.9), among 
Lactobacillus users, metronidazole (431 [89.79%]), fluoroquinolones (289 [60.21%]), 3rd 
and 4th generation cephalosporins (171 [35.63%]), broad spectrum penicillins (167 
[34.79%]), vancomycin (13; [27.08%]), and 1st generation cephalosporins (114 [23.75%]) 
were the most commonly prescribed antibiotics. The weighted frequencies (Table 4.9 and 
Figure 4.10) among Lactobacillus users were: fluoroquinolones (1,630 [63.57%]), 
metronidazole (1,294 [50.47%]), 1st generation cephalosporins (792 [30.88%]), 3rd and 4th 
generation cephalosporins (753 [29.36%]), broad spectrum penicillins (711 [27.72%]), 
macrolides (552; [21.54%]), and were the most commonly prescribed antibiotics. 
Antibiotic prescribing trend in the Lactobacillus non-users was almost the same as 
the overall sample. Generally, tetracyclines and other sulfonamides were the least 
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prescribed antibiotics. Almost all Lactobacillus users (431 [89.79%]) used metronidazole 
mainly for the CDI treatment. 
 
 
Table 4.8 – Distribution of antibiotic use in the total sample and in Lactobacillus users 
and non-users during total hospital stay [unweighted] 
 
Antibiotics classes  
Overall  Users  Non-users 
No. %  No. %  No. % 
Penicillins  3,644 10.22  71 14.79  3,573 10.15 
Penicillinase-resistant 
penicillins 
 550 1.54  23 4.79  527 1.50 
Broad spectrum penicillins  4,337 12.16  167 34.79  4,170 11.85 
1st gen. cephalosporins  8,883 24.90  114 23.75  8,769 24.92 
2nd gen. cephalosporins  1,583 4.44  19 3.96  1,564 4.44 
3rd & 4th gen. cephalosporins  5,327 14.93  171 35.63  5,156 14.65 
Carbapenems  2,059 5.77  80 16.67  1,979 5.62 
Aminoglycosides  3,530 9.90  82 17.08  3,448 9.80 
Fluoroquinolones  9,532 26.72  289 60.21  9,243 26.27 
Macrolides  2,467 6.92  85 17.71  2,382 6.77 
Tetracyclines  420 1.18  10 2.08  410 1.17 
Trimethoprim/Sulfamethoxazole  2,423 6.79  63 13.13  2,360 6.71 
Other sulfonamides  199 0.56  0 0.00  199 0.57 
Clindamycin  2,064 5.79  29 6.04  2,035 5.78 
Vancomycin  1,068 3.03  130 27.08  1,198 3.36 
Metronidazole  10,215 28.64  431 89.79  9,784 27.80 
Miscellaneous  2,951 8.27  91 18.96  2,860 8.13 
N: Number of users in each class of antibiotics; %: Percentage of users of each class of antibiotics to the total 
number of patients in the category. 
Note: Percentage do not sum to 100 because patients may receive more than one class of antibiotics.  An 
index for detail list of all antibiotics is provided in the appendix (A). 
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Table 4.9 – Distribution of antibiotic use in the total sample and in Lactobacillus users 
and non-users during total hospital stay [weighted] 
 
Antibiotics classes  
Overall  Users  Non-users 
No. %  No. %  No. % 
Penicillins  130,000 9.58  375 14.63  130,000 9.58 
Penicillinase-resistant penicillins*  16,000 1.18  222 8.65  16,000 1.17 
Broad spectrum penicillins*  92,000 6.62  711 27.72  91,000 6.58 
1st gen. cephalosporins  370,000 26.54  792 30.88  370,000 26.53 
2nd gen. cephalosporins  66,000 4.74  218 8.52  66,000 4.74 
3rd & 4th gen. cephalosporins*  120,000 8.69  753 29.36  120,000 8.65 
Carbapenems*  28,000 2.03  428 16.68  28,000 2.00 
Aminoglycosides*  110,000 7.61  453 17.67  110,000 7.60 
Fluoroquinolones*  250,000 18.16  1,630 63.57  250,000 18.07 
Macrolides*  72,000 5.15  552 21.54  71,000 5.12 
Tetracyclines  13,000 0.96  99 3.86  13,000 0.95 
Trimethoprim/Sulfamethoxazole*  60,000 4.34  370 14.41  60,000 4.33 
Other sulfonamides  3858 0.28  0 0.00  3858 0.28 
Clindamycin  73,000 5.24  128 4.98  73,000 5.24 
Vancomycin*  2413 0.17  338 13.17  2076 0.15 
Metronidazole*  85,000 6.15  1,294 50.47  84,000 6.07 
Miscellaneous*  80,000 5.77  596 23.25  80,000 5.74 
N: Number of users in each class of antibiotics; %: Percentage of users of each class of antibiotics to the total 
number of patients in the category. 
Note: Percentage do not sum to 100 because patients may receive more than one class of antibiotics.  An 
index for detail list of all antibiotics is provided in the appendix (A). 
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Distribution of Antibiotic Use and CDI status 
Among antibiotic users, the frequency and percentage of non-CDI, non-nosocomial 
CDI, and nosocomial CDI patients are described in Table 4.10 and Table 4.11. 
Antibacterial usage in the non-CDI group was mostly1st generation cephalosporin (7,086 
[26.54%]) and fluoroquinolones (4,746 [17.77%]) Vancomycin and tetracyclines were the 
least commonly prescribed antibiotics (Table 4.10 and Figure 4.10). 
Before weighting (Table 4.10), metronidazole (4,227 [95.46%]), fluoroquinolones 
(2,107 [47.58%]), 3rd & 4th generation cephalosporins (1,214 [27.42%]), broad spectrum 
penicillins (1,022 [23.08%]), and vancomycin (715 [16.15%]) were the most commonly 
prescribed antibiotics among non-nosocomial CDI cases. After applying the weight (Table 
4.11), the same antibiotics were most commonly prescribed. Other sulfonamides, 
penicillinase-resistant penicillins, and tetracyclines were the least prescribed antibiotics. 
In the nosocomial CDI patients before weighting (Table 4.10), metronidazole 
(4,485 [98.79%]), fluoroquinolones (2,679 [59.01%]), 3rd & 4th generation cephalosporins 
(1,830 [40.31%]), broad spectrum penicillins (1,552 [34.19%]), and 1st generation 
cephalosporins (1,311 [28.88%]) were most commonly prescribed antibiotics. After 
applying the weight (Table 4.11), the same antibiotics were most commonly prescribed. 
Tetracyclines and other sulfonamides were the least prescribed antibiotics. 
Generally tetracyclines and other sulfonamides were the least prescribed 
antibiotics. Almost all CDI cases used metronidazole, with (4,485 [98.59%]) of 
nosocomial cases and (4,227 [5.46%]) of non-nosocomial cases using the agent. This was 
most likely for CDI treatment. 
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Table 4.10– Distribution of antibiotic use in the non-CDI, non-nosocomial CDI, and 
nosocomial CDI patients [unweighted] 
 
Antibiotics classes  
Non-CDI  Non-nosocomial  Nosocomial 
No. %  No. %  No. % 
Penicillins  2,449 9.17  477 10.77  718 15.81 
Penicillinase-resistant penicillins  325 1.22  65 1.47  160 3.52 
Broad spectrum penicillins  1,763 6.60  1,022 23.08  1,552 34.19 
1st gen. cephalosporins  7,086 26.54  486 10.98  1,311 28.88 
2nd gen. cephalosporins  1,149 4.30  109 2.46  325 7.16 
3rd & 4th gen. cephalosporins  2,283 8.55  1,214 27.42  1,830 40.31 
Carbapenems  570 2.13  519 11.72  970 21.37 
Aminoglycosides  59.01 7.80  532 12.01  915 20.15 
Fluoroquinolones  4,746 17.77  2,107 47.58  2,679 59.01 
Macrolides  1,415 5.30  423 9.55  629 13.85 
Tetracyclines  241 0.90  77 1.74  102 2.25 
Trimethoprim/Sulfamethoxazole  1,139 4.27  511 11.54  773 17.03 
Other sulfonamides  95 0.36  36 0.81  68 1.50 
Clindamycin  1,361 5.10  214 4.83  489 10.77 
Vancomycin  27 0.10  715 16.15  456 10.04 
Metronidazole  1,503 5.63  4,227 95.46  4,485 98.79 
Miscellaneous  1,588 5.95  498 11.25  865 19.05 
N: Number of users in each class of antibiotics; %: Percentage of users of each class of antibiotics to the total 
number of patients in the category. 
Note: Percentage do not sum to 100 because patients may receive more than one class of antibiotics. 
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Table 4.11– Distribution of antibiotic use in the non-CDI, non-nosocomial CDI, and 
nosocomial CDI patients [weighted] 
 
Antibiotics classes  
Non-CDI  Non-nosocomial  Nosocomial 
No. %  No. %  No. % 
Penicillins*  130,000 9.56  477 10.77  718 15.81 
Penicillinase-resistant penicillins*  16,000 1.17  65 1.47  160 3.52 
Broad spectrum penicillins*  89,000 6.47  1,022 23.08  1,552 34.19 
1st gen. cephalosporins*  370,000 26.58  486 10.98  1,311 28.88 
2nd gen. cephalosporins*  65,000 4.74  109 2.46  325 7.16 
3rd & 4th gen. cephalosporins*  120,000 8.52  1,214 27.42  1,830 40.31 
Carbapenems*  27,000 1.93  519 11.72  970 21.37 
Aminoglycosides*  100,000 7.56  532 12.01  915 20.15 
Fluoroquinolones*  250,000 17.93  2,107 47.58  2,679 59.01 
Macrolides*  70,000 5.11  423 9.55  629 13.85 
Tetracyclines*  13,000 0.95  77 1.74  102 2.25 
Trimethoprim/Sulfamethoxazole*  59,000 4.28  511 11.54  773 17.03 
Other sulfonamides*  3754 0.27  36 0.81  68 1.50 
Clindamycin*  72,000 5.23  214 4.83  489 10.77 
Vancomycin*  1242 0.09  715 16.15  456 10.04 
Metronidazole*  77,000 5.56  4,227 95.46  4,485 98.79 
Miscellaneous*  79,000 5.71  498 11.25  865 19.05 
N: Number of users in each class of antibiotics; %: Percentage of users of each class of antibiotics to the total 
number of patients in the category. 
Note: Percentage do not sum to 100 because patients may receive more than one class of antibiotics. 
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Description of Lactobacillus and Antibiotic Initiation Dates 
Table 4.12 and Figure 4.9 show the description of the day on which Lactobacillus 
was initiated with respect to antibiotic initiation dates among non-CDI, non-nosocomial 
CDI, and nosocomial CDI patients. Over half of the non-CDI patients used Lactobacillus 
five or more days after initiation of antibiotic therapy and (11 [30.56%]) started 
Lactobacillus on or before the same day antibiotics were initiated. Similar to the non-CDI 
group, the majority of non-nosocomial CDI patients started Lactobacillus five or more 
days after antibiotic therapy was initiated; (86 [42.36%]). Also, the number of those who 
used it on the same day or one day after antibiotic therapy was initiated was relatively high 
at 36 (17.73%) and 25 (12.33%), respectively. In nosocomial CDI cases the majority (151 
[80.32%]) started Lactobacillus five or more days after antibiotic therapy was initiated. In 
general, Lactobacillus was mostly initiated five days or more after antibiotic therapy was 
initiated (256 [59.95%]) or at the same day antibiotic therapy was initiated (59 [13.82%]).   
 
61 
 
Table 4.12 – Description of the day Lactobacillus was initiated with respect to 
antibiotic initiation date 
 
Initiation of 
antibiotic 
therapy 
 
No CDI 
(n=36)  
Non-nosocomial 
CDI 
(n= 203)  
Nosocomial 
CDI  
(n=188) 
 
 
Total 
(n= 427) 
 No. (%)  No. (%)  No. (%)  No. (%) 
Before*  5 (13.89)  15 (7.39)  9 (4.79)  29 (6.79) 
Same day  6 (16.67)  36 (17.73)  17 (9.04)  59 (13.82) 
One day after  2 (5.56)  25 (12.33)  3 (1.60)  30 (7.03) 
Two days after  0 (0.00)  13 (6.40)  2 (1.06)  15 (3.51) 
Three days after  1 (2.78)  16 (7.88)  4 (2.13)  21 (4.92) 
Four days after  3 (8.33)  12 (5.91)  2 (1.06)  17 (3.98) 
Five or more 
days after  
19 (52.77)  86 (42.36)  151 (80.32)  256 (59.95) 
CDI: Clostridium difficile infection. 
*Lactobacillus has been initiated before antibiotics therapy was initiated. 
Note: Only patients who used the Lactobacillus were included in this table. Total number of patients in this 
table is less than total Lactobacillus users since 53 patients used Lactobacillus but not antibiotics. 
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Figure 4.9 – Number of days between initiation of Lactobacillus and the start dates of 
antibiotics in overall sample 
 
62 
 
Description of Lactobacillus and CDI Treatment Initiation Dates 
Table 4.13 and Figure 4.10 show the description of the day Lactobacillus was 
initiated with respect to CDI treatment (metronidazole or vancomycin) initiation dates 
among non-nosocomial and nosocomial CDI cases. Among the non-nosocomial cases, the 
majority started Lactobacillus five or more days after CDI treatment was initiated (95 
[40.08%]). Also, those who started Lactobacillus on the same day or one day after CDI 
treatment was initiated were relatively high at (61 [25.74%]) and (27 [11.39%]), 
respectively. In the nosocomial CDI cases, the majority started Lactobacillus either before 
(4; [20.79%]) or on the same day (42 [20.79%]) that CDI treatment was initiated. Also, the 
percentage of those who started it five days or more after CDI treatment was initiated was 
high; (76 [37.62%]). In general, Lactobacillus was mostly initiated five days or more after 
CDI treatment was initiated (171 [38.95%]) or on the same day CDI treatment was 
imitated (103 [23.46%]). 
63 
 
Table 4.13 – Description of the day Lactobacillus was initiated with respect to CDI 
treatment initiation date 
 
Initiation of CDI 
treatment 
 
Non-nosocomial 
CDI (n= 237)  
Nosocomial CDI 
(n= 202)  
Total 
(n= 439) 
 No. (%)  No. (%)  No. (%) 
Before*  15 (6.33)  42 (20.79)  57 (12.98) 
Same day  61 (25.74)  42 (20.79)  103 (23.46) 
One day after  27 (11.39)  20 (9.90)  47 (10.71) 
Two days after  19 (8.02)  8 (3.96)  27 (6.15) 
Three days after  12 (5.06)  7 (3.47)  19 (4.33) 
Four days after  8 (3.38)  7 (3.47)  15 (3.42) 
Five or more days after  95 (40.08)  76 (37.62)  171 (38.95) 
CDI: Clostridium difficile infection. 
*Lactobacillus has been initiated before antibiotics therapy was initiated. 
Note: Only CDI patients who used the Lactobacillus were included in this table. Total number of patients in 
this table is less than Lactobacillus users since 39 patients who used Lactobacillus did not develop CDI. 
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Figure 4.10 – Number of days between initiation of Lactobacillus and the start dates 
of CDI treatment in the cases 
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Crude Analysis of the Relationship Between Lactobacillus and CDI outcomes 
The crude analysis of the relationship between the use of Lactobacillus and the 
outcomes of interest in nosocomial CDI patients is shown in Table 4.11. The crude 
analysis showed a significant relationship between Lactobacillus and post CDI diagnosis 
length of stay (β = 8.643; 95% CI 5.744 to 11.542; P < 0.001). Use of Lactobacillus is 
associated with an increase in post-CDI-diagnosis length of stay by approximately eight 
days. The crude analysis showed a significant protective effect of Lactobacillus use of the 
switch rate of CDI treatment (OR= 0.159; 95% CI 0.037 to 0.684; P = 0.014). Those who 
used Lactobacillus were about 6 times less likely to switch CDI therapy than non-users. 
There was no significant relationship between Lactobacillus use and readmission for CDI 
or mortality. 
 
 
 
Table 4.14 – The crude relationships between CDI related outcomes and the use of 
Lactobacillus  
Outcomes Estimatea (SE) P-value 95 % CI 
Post diagnosis length of stay 8.643 (1.479) < 0.001 (5.744, 11.542) 
Switch rateb 0.159 (0.118) 0.014 (0.037, 0.684) 
Readmission 1.310 (0.229) 0.124 (0.930, 1.845) 
Mortality 0.946 (0.223) 0.822 (0.584, 1.533) 
aEstimate for length of stay is regression coefficient and others are odds ratios; bOnly patients who used 
Lactobacillus after CDI diagnosis were considered (440 patients). 
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Adjusted Analysis of the Relationship Between Lactobacillus and CDI Outcomes 
The adjusted analysis of the relationship between Lactobacillus and the outcomes 
of interest in nosocomial CDI patients are shown in Tables 4.12 and 4.13. After adjusting 
for all available potential confounders in a logistic regression model, Lactobacillus use was 
still significantly associated with an increase in post-CDI-diagnosis length of stay (β 
=5.672; 95% CI 3.183 to 8.161; P < 0.001). The strength of the association, however, was 
reduced when compared to the crude analysis (from 8.643 days to 5.672 days). After 
adjustment, Lactobacillus use increases the post-diagnosis length of stay by about 5 days. 
For the assessment of the adjusted relationship between Lactobacillus use and mortality, 
severity of illness was re-categorized to two categories (minor/moderate, major/extreme) 
because of large differences in patients in those groups. After adjustment, Lactobacillus 
use was still significantly associated with a reduction in the likelihood of switching CDI 
treatment (OR= 0.166; 95% CI 0.037 to 0.740; P = 0.019). There was not a large 
difference in the strength of the association the crude and adjusted analysis. Lactobacillus 
use was not significantly associated with readmission for CDI (OR= 1.376; 95% CI 0.970 
to 1.951; P 0.074) after adjusting for potential confounders in a logistic regression model. 
As in the crude relationship, Lactobacillus use was not significantly associated with 
mortality (OR= 0.736; 95% CI 0.510 to 1.063; P = 0.103) after adjusting for all available 
potential confounders in a logistic regression model. Detailed tables with the output of the 
four regression models used in this analysis are included in Appendix A 
.
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Table 4.15 – Adjusted relationship between Lactobacillus use and length of stay and 
likelihood of switching CDI treatment 
 
Independent variables 
 Length of stay  Switch rate 
 β (95% CI) P-value  OR (95% CI) P-value 
Lactobacillus use  5.672 
(3.183,8.161) 
< 0.001  0.166 
(0.037, 0.740) 
0.019 
Age (years)  -0.071 
(-0.10, -0.04) 
< 0.001  1.002 
(0.983, 1.022) 
0.841 
Sex  -0.080 
(-1.13, 0.97) 
0.882  1.412 
(0.723, 2.757) 
0.313 
Race:   0.350   0.054 
Caucasian (Ref.)  —   —  
African American  0.624 
(-0.754, 2.002) 
  4.097 
(0.968, 17.335) 
 
Other  1.010 
(-0.509, 2.529) 
  0.938 
(0.403, 2.181) 
 
Transfer from outside 
hospital 
 1.532 
(-1.952, 5.016) 
0.389  0.953 
(0.127, 7.151) 
0.962 
Switched CDI treatment  0.260 
(-5.235, 5.755) 
0.926  N/A N/A 
Severity of illness:   < 0.001   0.406 
Minor/Moderate (Ref.)  —   —  
Major  1.935 
(0.190, 3.679) 
  0.562 
(0.159, 1.990) 
 
Extreme  6.809  
(5.111, 8.506) 
  0.565 
(0.162, 1.972) 
 
ICU-days  0.679 
(0.642, 0.717) 
< 0.001  1.015 
(0.985, 1.046) 
0.320 
Charlson score  0.087 
(-0.124, 0.298) 
0.420  1.029 
(0.897, 1.179) 
0.686 
Mortality  -0.009 
(-1.844, 1.826) 
0.993  0.839 
(0.280, 2.513) 
0.754 
Constant  8.368 
(2.459, 14.277) 
0.006  N/A  
OR: Odds ratio; β: Regression coefficient; CI: Confidence interval; SOI: Severity of illness; ICU-days: 
Number of intensive care unit days; N/A: not applicable. 
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Table 4.16 – Adjusted relationship between Lactobacillus use and readmission and 
mortality 
 
Independent variables 
 Readmission  Mortality 
 OR (95% CI) P-value  OR (95% CI) P-value 
Lactobacillus use  1.376 
(0.970, 1.951) 
0.074  0.736 
(0.510, 1.063) 
0.103 
Age (years)  0.998 
(0.994, 1.003) 
0.469  1.019 
(1.014, 1.024) 
<0.001 
Sex  0.865 
(0.738, 1.013) 
0.072  0.910 
(0.780, 1.063) 
0.234 
Race:   0.287   0.2421 
Caucasian (Ref.)  —   —  
African American  1.086 
(0.887, 1.330) 
  0.878 
(0.717, 1.075) 
 
Other  0.870 
(0.687, 1.101) 
  0.851 
(0.669, 1.082) 
 
Transfer from outside 
hospital 
 0.601 
(0.318, 1.138) 
0.118  1.590 
(1.089, 2.321) 
0.016 
Switched CDI treatment  1.560 
(0.605, 4.021) 
0.358  0.732 
(0.408, 1.315) 
0.297 
Severity of illness:   0.591   <0.001 
Minor/Moderate (Ref.)  —   —  
Major  1.062 
(0.820, 1.375) 
  N/A*  
Extreme  1.155 
(0.899, 1.486) 
  16.525 
(7.364, 37.081) 
 
ICU-days  0.985 
(0.978, 0.993) 
< 0.001  1.032 
(1.027, 1.036) 
< 0.001 
Charlson score  0.986 
(0.955, 1.019) 
0.405  1.119 
(1.089, 1.150) 
< 0.001 
Mortality  0.393 
(0.270, 0.571) 
< 0.001  N/A N/A 
Constant  N/A   N/A  
OR: Odds ratio; CI: Confidence interval; SOI: Severity of illness; ICU-days: Number of intensive care unit 
days; N/A: not applicable. 
*Severity of illness was re-categorized to two categories (minor/moderate, major/extreme) to reduce the 
variability. 
 
  
68 
 
 
 
 
 
CHAPTER 5: DISCUSSION 
 
 
Incidence and severity of CDI has been continuously increasing in the United 
States over the last decade.47 This is a debilitating illness with a high cost, especially 
among recurrent CDI cases. The literature shows some evidence of the beneficial effects of 
probiotics in treatment of CDI through its ability to restore the balance in the normal flora 
that have been disrupted by the prior use of antibiotics 
This retrospective cohort study gives a detailed description of the characteristics of 
Lactobacillus users and non-users among CDI cases and non-cases. This is the first study 
to describe in detail probiotics users. This study found that almost all Lactobacillus users 
were patients with CDI indicating that the use of Lactobacillus may be mainly for 
treatment of CDI and not prevention of it. Also most all Lactobacillus users (89.16%) had 
either major or extreme severity of illness unlike the non-users who had mainly minor or 
moderate severity of illness. This also supports the conclusion that Lactobacillus is only 
prescribed for severe cases of CDI. As the severity of illness increased, the frequency of 
Lactobacillus use increased. The opposite relationship was true for the severity of illness 
and number of Lactobacillus non-users. Additionally, it was found that users were 
significantly different from non-users in age, number of antibiotics received, mortality, 
readmission, and length of stay. Users were significantly older (mean age = 61.09; 95% CI 
59.46 to 62.71) than non users (mean age = 53.78; 95% CI53.85 to 53.98). As the number 
69 
 
of antibiotics received increased, the frequency of Lactobacillus use increased. The 
opposite relationship was true for the number of antibiotics received and number of 
Lactobacillus non-users. Readmission and length of stay were significantly higher for 
Lactobacillus users than non-users. All of these risk factors are associated with CDI and 
consequently with the use of Lactobacillus and are consistent with the reported risk factors 
in the literature12, 57, 58 In both users and non-users, IDC-9-CM code (008.45) for CDI was 
among the top diagnosis codes in general because the sample was selected based on that 
code.  
This study found that certain antibiotic classes (metronidazole, fluoroquinolones, 
3rd and 4th generation cephalosporins, broad spectrum penicillins, vancomycin, and 1st 
generation cephalosporins) were used most frequently by Lactobacillus users. This 
supports the published literature that describes classes of antibiotics associated with CDI.52, 
53, 56 
 That could introduce bias in the ability of determining the effects of Lactobacillus on 
CDI related outcomes. The results are also consistent with prior research findings that 
hospital-acquired CDI is related to age, time spent in the hospital (before the diagnosis 
date), use of proton pump inhibitors, and gastrointestinal disease. 
Analytical weights were used in the analysis to account for the random sampling 
approach in the original risk factor study. These weights allowed each individual to be 
representative of the actual number of patients in the UHC population. For that reason the 
there were large differences between weighted Lactobacillus users who were non-CDI 
patients (n = 2,125 [82.88%]) and unweighted Lactobacillus users non-CDI patients (41 
[8.54%]) 
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There was evidence of a statistically significant relationship between Lactobacillus 
use and post-CDI-diagnosis length of stay. Lactobacillus users were expected to have 
longer length of stay than non-users. However, the direction of these relationships was 
unexpected. This could be explained by the fact most of CDI cases were older and more 
severely ill than non-CDI patients. All of these factors may have driven the relationship in 
the unexpected direction even after accounting for it in a regression model. Also, there was 
a statistically significant relationship between Lactobacillus use and switch rate of CDI 
treatment. Non-users were about 6 times more likely to switch their CDI treatment than 
users. Lactobacillus use was not significantly associated with either readmission for CDI 
or mortality. Switch rate of CDI treatment was selected as an outcome variable because it 
could be used as a marker of CDI treatment failure. Patients who are cured on oral 
metronidazole usually switch to oral vancomycin. From the descriptive part of this study, it 
is clear that Lactobacillus was mainly prescribed for the sicker patients as a last resort 
treatment. However, literature shows that probiotics are better for prevention of CDI than 
treatment. This fact may also have reduced the ability of detecting the true relationship and 
may have driven it in the unexpected direction. 
The large sample size used in this study theoretically allowed for a high power to 
detect the association between Lactobacillus use and the outcome variables of interest. 
Given the significant differences between Lactobacillus users and non-users, more 
complex models would need to be conducted with an observational data to estimate more 
appropriately the relationship between Lactobacillus use and the CDI-related outcomes. 
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Limitations 
Even though the data used in this study came from different hospitals around the 
nation, there is a considerable variation in the number of participating hospitals each year. 
That variability may have introduced bias in that they may have had greatly different 
characteristics with regards to antibiotic and Lactobacillus use. Elimination of these 
hospitals would have greatly reduced the sample size. Considering that all the hospitals in 
this study were from academic healthcare centers, the finding may not be generalizable to 
other non-academic hospitals. 
C. difficile is one of most commonly indentified causes of nosocomial diarrhea. It is 
certain that infection control practices such as gloves, hand washing, and disinfectant use 
may affect the rates of infection. The data used in this study do not include such 
information, and therefore it was not accounted for in the regression models used in the 
analysis. 
Another potential limitation is the lack of laboratory information that might help in 
confirming the diagnosis of CDI. The CRM database was developed for administrative 
purposes and does not include laboratory results. Because of that limitation confirmation of 
ICD-9-CM codes with laboratory assay results for CDI was not done. Instead, cases were 
indentified based on the ICD-9-CM code (008.45) for CDI using a recently developed and 
validated definition by Schmiedeskamp et al.77 Another potential limitation is that the 
validity of the drug usage data in the UHC CRM database has been examined in only one 
participating hospital.  
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Lactobacillus users and non-users were very different since they were not matched 
to each other. Instead, CDI cases and controls were matched on the hospital and quarter in 
which they were discharged. This variability between Lactobacillus users and non-users is 
an issue for the analytical parts, but not really for the descriptive piece. In this study 
Lactobacillus use was not classified as before or after-CDI-diagnosis since there was only 
small number of patients who used it before-CDI-diagnosis. That did not allow assessment 
of Lactobacillus use as a prevention therapy. 
Another limitation is that the direction of switch of therapy was not measure. 
Switching from metronidazole to vancomycin or vancomycin to metronidazole was 
considered the same. However, that could have different meaning. Switching from 
metronidazole to vancomycin represents treatment failure while switching from 
vancomycin to metronidazole does not. 
 
Future Directions 
The descriptive findings from this study provide information on the general 
characteristics of Lactobacillus users that could be used as a foundation for generating 
hypothesis for future research in this field. The population of this study was adult 
hospitalized patients. A future descriptive study on hospitalized children could be 
conducted.  
This study also attempted to identify the relationship between the use Lactobacillus 
and several CDI related outcomes. Due to the large differences between CDI cases and the 
controls the true relationships were difficult to identify. To overcome this problem, 
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modification in the design or the analysis of the study should be considered in the future 
studies. Matching on more variables in a retrospective or a prospective cohort or case 
control studies will reduce the variability and might better identify the true relationships 
between Lactobacillus use and various CDI related outcomes. If the there were significant 
relationship after a prospective study, a randomized clinical trial with sufficient sample 
size should be conducted for more accurate assessment of the true relationship. In addition, 
propensity score method could account for more variability between Lactobacillus users 
and non-users. 
 
Conclusions 
Lactobacillus users and non-users were different in most characteristics. 
Lactobacillus use by CDI cases was high and mainly started on the same day or before 
initiation of antibiotics. Lactobacillus use was associated with increased length of stay and 
switch of CDI therapy. Although this study describes the types of patients who are 
receiving Lactobacillus, the true association between Lactobacillus use and CDI-related 
outcomes remains unclear and further research is needed.  
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Table A.1 – Adjusted relationship between Lactobacillus use and post CDI diagnosis 
post length of stay 
 
Independent variables β SE t P-value 
95 % Confidence 
Intervals 
Lower Upper 
Lactobacillus use  5.672 1.270 4.47 < 0.001 3.183 8.161 
Age (year) -0.071 0.016 -4.42 < 0.001 -0.102 -0.039 
Sex -0.080 0.535 -0.15 0.882 -1.129 0.970 
Race:    0.350   
Caucasian (Ref.) — — —  — — 
African American 0.624 0.703 0.89  -0.754 2.002 
Other 1.010 0.775 1.30  -0.509 2.529 
Transfer from outside 
hospital 1.532 1.777 0.86 0.389 -1.952 5.016 
Switched CDI treatment 0.260 2.803 0.09 0.926 -5.235 5.755 
Severity of illness:    < 0.001   
Minor/Moderate 
(Ref.) 
— — —  — — 
Major 1.935 0.890 2.17  0.190 3.679 
Extreme 6.809 0.866 7.86  5.111 8.506 
ICU-days 0.679 0.019 35.57 < 0.001 0.642 0.717 
Charlson score 0.087 0.108 0.81 0.420 -0.124 0.298 
Mortality -0.009 0.936 -0.01 0.993 -1.844 1.826 
Constant 8.368 3.014 2.78 0.006 2.459 14.277 
No. observations = 4,345; F (12, 4,332) = 148.05; p < 0.001; R2 = 0.291; Adjusted R2 = 0.289 
β: Regression coefficient; SE: Standard error; ICU-days: Number of intensive care unit days; CDI: C. 
difficile infection. 
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Table A.2 – Adjusted relationship between Lactobacillus use and the likelihood of 
switching CDI treatment  
 
Independent variables OR SE Z P-value 
95 % Confidence 
Intervals 
Lower Upper 
Lactobacillus use 0.166 0.126 -2.350 0.019 0.037 0.740 
Age (year) 1.002 0.010 0.200 0.841 0.983 1.022 
Sex 1.412 0.482 1.010 0.313 0.723 2.757 
Race:    0.054   
Caucasian (Ref.) — — —  — — 
AfricanAmerican 4.097 3.015 1.920  0.968 17.335 
Other 0.938 0.404 -0.150  0.403 2.181 
Transfer from outside 
hospital 0.953 0.980 -0.050 0.962 0.127 7.151 
Severity of illness:    0.406   
Minor/Moderate 
(Ref.) 
— — —  — — 
Major 0.562 0.363 -0.890  0.159 1.990 
Extreme 0.565 0.360 -0.900  0.162 1.972 
ICU-days 1.015 0.016 0.990 0.320 0.985 1.046 
Charlson score 1.029 0.072 0.400 0.686 0.897 1.179 
Mortality 0.839 0.470 -0.310 0.754 0.280 2.513 
No. observations = 4,186; Log likelihood = -209.99; Likelihood ratio χ2 = 13.01; p = 0.292 
OR: Odds ratio;CI: Confidence interval; SE: Standard error; ICU-days: Number of intensive care unit days; 
CDI: C. difficile infection. 
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Table A.3 – Adjusted relationship between Lactobacillus use and readmission  
 
Independent variables OR SE Z P-value 
95 % Confidence 
Intervals 
Lower Upper 
Lactobacillus use 1.376 0.245 1.79 0.074 0.970 1.951 
Age (year) 0.998 0.002 -0.72 0.469 0.994 1.003 
Sex 0.865 0.070 -1.80 0.072 0.738 1.013 
Race:    0.287   
Caucasian (Ref.) — — —  — — 
African American 1.086 0.112 0.80  0.887 1.330 
Other 0.870 0.105 -1.16  0.687 1.101 
Transfer from outside 
hospital 
0.601 0.196 -1.56 0.118 0.318 1.138 
Switched CDI treatment  1.560 0.754 0.92 0.358 0.605 4.021 
Severity of illness:    0.436   
Minor/Moderate 
(Ref.) 
— — —  — — 
Major 1.062 0.140 0.46  0.820 1.375 
Extreme 1.155 0.148 1.13  0.899 1.486 
ICU-days 0.985 0.004 -3.91 < 0.001 0.978 0.993 
Charlson score 0.986 0.016 -0.83 0.405 0.955 1.019 
Mortality 0.393 0.075 -4.90 < 0.001 0.270 0.571 
No. observations = 4,345; Log likelihood = -2020.44; Likelihood ratio χ2 = 67.33; p < 0.001 
OR: Odds ratio; CI: Confidence interval; SE: Standard error; ICU-days: Number of intensive care unit days; 
CDI: C. difficile infection. 
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Table A.4 – Adjusted relationship between Lactobacillus use and mortality 
 
Independent variables OR SE Z P-value 
95 % Confidence 
Intervals 
Lower Upper 
Lactobacillus use  0.736 0.138 -1.63 0.103 0.510 1.063 
Age (year) 1.019 0.003 7.72 <0.001 1.014 1.024 
Sex 0.910 0.072 -1.19 0.234 0.780 1.063 
Race:    0.2421   
Caucasian (Ref.) — — —  — — 
African American 0.878 0.091 -1.26  0.717 1.075 
Other 0.851 0.104 -1.32  0.669 1.082 
Transfer from outside 
hospital 
1.590 0.307 2.40 0.016 1.089 2.321 
Switched CDI treatment  0.732 0.219 -1.04 0.297 0.408 1.315 
Severity of illness:    <0.001   
Minor/Moderate 
(Ref.) 
— — —  — — 
Major /Extreme 16.525 6.814 6.80  7.364 37.081 
ICU-days 1.032 0.002 13.68 <0.001 1.027 1.036 
Charlson score 1.119 0.016 8.00 <0.001 1.089 1.150 
No. observations = 4,345; Log likelihood = -2020.44; Likelihood ratio χ2 = 67.33; p < 0.001 
OR: Odds ratio; CI: Confidence interval; SE: Standard error; ICU-days: Number of intensive care unit days; 
CDI: C. difficile infection. 
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